The chemokine receptor type 4 antagonist, AMD3100, interrupts experimental tooth movement in rats

The chemokine receptor type 4 antagonist, AMD3100, interrupts experimental tooth movement in rats
复制标题

DOI:
10.1016/j.archoralbio.2017.11.003
复制
发表时间:
2018-02-01
影响因子:
3
通讯作者:
Ono, Takashi
Ono, Takashi
中科院分区:
医学4区
文献类型:
--
作者:
Hatano, Kasumi;Ishida, Yuji;Ono, Takashi

文献摘要

被引文献

相似文献

目的:本研究的目的是阐明基质细胞衍生因子-1(SDF-1)/C-X-C趋化因子受体4型(CXCR 4)轴在破骨细胞积聚中的作用,以及通过给予CXCR 4拮抗剂AMD 3100对牙周组织施加机械力时正畸牙齿移动(OTM)的影响。设计:用10 g力的钛镍闭合螺旋弹簧移动大鼠右上第一磨牙(M1)。用磷酸盐缓冲盐水或AMD 3100(5 mg/kg)(一种SDF-1拮抗剂)处理大鼠。0,1,3,7天后,在所有组的牙槽骨进行了检查,在每个时间点,通过微型计算机断层扫描和组织学analysis.Results:牙齿移动减少显着在AMD 3100治疗组在1,3,7天后开始OTM。与对照组相比,治疗组第1天和第3天M1周围牙周膜中抗酒石酸酸性磷酸酶阳性多核细胞数量显著减少。结论:AMD 3100可减少正畸力作用下大鼠磨牙OTM和破骨细胞的积聚。这些结果表明,SDF-1/CXCR 4轴在OTM牙槽骨代谢中起着重要作用。
Objective: The aim of this study was to clarify the role of the stromal cell-derived factor-1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4) axis in osteoclast accumulation, and the influence of orthodontic tooth movement (OTM) under mechanical force application to periodontal tissues, by administration of the CXCR4 antagonist AMD3100.Design: The upper right first molar (M1) of rats was moved menially with a 10-g force titanium-nickel closed coil spring. Rats were treated with phosphate-buffered saline or AMD3100 (5 mg/kg), which is a SDF-1 antagonist. After 0, 1, 3, and 7 days, alveolar bones in all groups were examined at each time point by micro-computed tomography and histological analysis.Results: Tooth movement was decreased significantly in the AMD3100-treated group at 1, 3, and 7 days after beginning OTM. The numbers of tartrate-resistant acid phosphatase-positive multinucleated cells in the periodontal ligament around the maxillary M1 were decreased significantly in the treated as compared to the control group on Days 1 and 3.Conclusion: Administration of AMD3100 decreases OTM and osteoclast accumulation in rat molars under orthodontic force application. These findings suggest that the SDF-1/CXCR4 axis plays an important role in alveolar bone metabolism during OTM.